Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of ...

Leerink Partners analyst Andrew Berens has maintained their bullish stance on MRUS stock, giving a Buy rating yesterday.Pick the best stocks ...

We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...

Merus (NASDAQ:MRUS – Get Free Report) had its price target hoisted by research analysts at Citigroup from $89.00 to $97.00 in ...

Netherlands-based clinical-stage biotech Merus on Saturday announced interim clinical data as of a July 5, 2024 data cutoff ...

Needham & Company LLC reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $85.00 price target on the ...

Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or ...

Get top local stories in Southern California delivered to you every morning. Sign up for NBC LA's News Headlines newsletter.

Bizengri (zenocutuzumab) targets the NRG1 gene and has been cleared by the FDA to treat advanced pancreatic adenocarcinoma ...

The U.S. Food and Drug Administration has approved Merus NV's therapy that targets a particular gene, expanding treatment ...

It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed. Allison Transmission: "Storied ...

Get top local stories in DFW delivered to you every morning. >Sign up for NBC DFW's News Headlines newsletter. Merus: "It is still very, very speculative." Click here to download Jim Cramer's ...